18 <strong>BIO</strong>.<strong>NRW</strong>
<strong>BIO</strong>.<strong>NRW</strong> enabled to enter the market significantly faster. In additi<strong>on</strong>, CLIB 2021 c<strong>on</strong>tinues to expand its internati<strong>on</strong>al network to successfully c<strong>on</strong>duct R&D projects with partner regi<strong>on</strong>s: the cluster runs representati<strong>on</strong>s in Canada (2009), Russia (2010) and Brazil (2011). 20 % of its members are internati<strong>on</strong>al - from Europe, North-America and Russia. CLIB 2021 addresses several key areas of innovati<strong>on</strong> like “polyomics”, strain development, fermentati<strong>on</strong>, biocatalysis and expressi<strong>on</strong>, downstream processing, carb<strong>on</strong> source transformati<strong>on</strong> and biotechnological intermediates. The cluster supports R&D c<strong>on</strong>sortia, cooperati<strong>on</strong> partners, entrepreneurs and young researchers to bring biotechnological innovati<strong>on</strong>s to the market. With its goal to turn research results most effectively into commercially successful innovati<strong>on</strong>, CLIB 2021 is aspiring to become the leading European cluster in industrial biotechnology. Pharmaceutical <strong>Biotechnology</strong> – <strong>BIO</strong>.<strong>NRW</strong>.red In the last decades, major milest<strong>on</strong>es in the progress of medicine and healthcare have been achieved by the applicati<strong>on</strong> of pharmaceutical (“red”) biotechnology, namely in the development of drugs, vaccines and diagnostics. Germany is the “European Champi<strong>on</strong>” in producti<strong>on</strong> of biopharmaceuticals and world wide the clear number two behind the USA. 20 different, already approved active ingredients are produced in Germany. 8 In 2010 six out of 22 newly approved drugs (27 percent) were biopharmaceuticals and at the end of the year 198 biopharmaceuticals had a market authorisati<strong>on</strong> for Germany. The main fields of therapy with regard to the total pharmaceutical market in the indicati<strong>on</strong> are immunology (74 percent), metabolism (35 percent) and <strong>on</strong>cology (32 percent). The sales of biopharmaceuticals increased in Germany by 10.6 percent to about EUR 5.2 billi<strong>on</strong> and this corresp<strong>on</strong>ds to 17 percent of the total pharmaceutical market in 2010. The majority of the German biotech companies are dedicated to the research for new diagnostic methods and drug development. In 2010, 250 of all 538 dedicated German biotech companies (46.5 percent) were active in red biotechnology. 9 For more than a century, North Rhine-Westphalia has been the heartland of Germany’s pharmaceutical industry. The state houses a significant number of companies that develop pharmaceuticals and has an excepti<strong>on</strong>al standard in biotechnological and medical educati<strong>on</strong>. This advantage, combined with the enormous market potential of biopharmaceuticals, inspired <strong>BIO</strong>.<strong>NRW</strong>’s strategic initiative in the field of red biotechnology called <strong>BIO</strong>. <strong>NRW</strong>.red. Its starting point was the competiti<strong>on</strong> “Bio.<strong>NRW</strong> 2009”, announced by <strong>NRW</strong>’s Ministry of Innovati<strong>on</strong>, Science and Research to foster the formati<strong>on</strong> of c<strong>on</strong>sortia between academia and biotech companies. The successful projects can be grouped into the following main categories: development of drugs (biologicals and small molecules), generati<strong>on</strong> of new methods in diagnostics, establishment of biomarkers and introducti<strong>on</strong> of new biopharmaceutical processes – based <strong>on</strong> cell cultures for example. An additi<strong>on</strong>al initiative by the federal Ministry of Innovati<strong>on</strong>, Science and Research, the competiti<strong>on</strong> PerMed.<strong>NRW</strong>, focused <strong>on</strong> pers<strong>on</strong>alised medicine started at the end of 2010. Apart from this substantial support for the further development of <strong>BIO</strong>. <strong>NRW</strong>.red the strategic initiative will c<strong>on</strong>tinue regular meetings to nurture and maintain the dialogue between experts in science and business as well as specific strategies to improve the financial support for start-up companies and small and medium enterprises in the field. The overall aim of the <strong>BIO</strong>.<strong>NRW</strong>.red is to c<strong>on</strong>tinue and extend the sustainable network that c<strong>on</strong>nects all important players in the field of medicine, healthcare, pharmaceutical industry and red biotechnology. From Mind to Market This chapter provides an overview of 51 of the dedicated and 12 of the other biotechnologically active companies from North Rhine-Westphalia as classified following the OECD guidelines (page 57). For c<strong>on</strong>venience, the companies are grouped in five areas according to their main business: N<strong>on</strong>-specific Services Health and Medicine (including Animal Health) Industrial <strong>Biotechnology</strong> Agri/Agrobiotechnology Bioinformatics For a more comprehensive directory that includes all life science companies in <strong>NRW</strong>, please visit our company database at www. bio.nrw.de/firmendatenbank. <strong>BIO</strong>.<strong>NRW</strong> invites you to discover North Rhine-Westphalia‘s biotechnology community! Sources, Literature, Links [1] www.nrwinvest.com/nrwinvest_deutsch/ <strong>NRW</strong>_im_Ueberblick/ [2] Analysis by <strong>BIO</strong>.<strong>NRW</strong> [3] OECD <strong>Biotechnology</strong> Statistics 2010, B. van Beuzekom and A. Arundel [4] <strong>NRW</strong> PCT Biotech Patent Analysis by <strong>BIO</strong>.<strong>NRW</strong> [5] www.biotechnologie.de [6] www.biotechgate.com; Venture Valuati<strong>on</strong>, Zurich, CH [7] Industrial <strong>Biotechnology</strong> (2010); Jarell, K. A.: Synthetic biology and the sustainable chemistry revoluti<strong>on</strong>. (5) No. 4 [8] Biopharmazeutika – Hightech im Dienst des Patienten; Verband Forschender Arzneimittelhersteller e. V.; www.vfa.de/de/presse/ publikati<strong>on</strong>en [9] BCG Report Medizinische Biotechnologie in Deutschland 2011 – Biopharmazeutika: Wirtschaftsdaten und Nutzen der Pers<strong>on</strong>alisierten Medizin; Dr. Max v<strong>on</strong> Holleben, Dr. Michael Pani, Dr. Axel Heinemann; www.vfa.de/de/presse/publikati<strong>on</strong>en 19